RALEIGH, N.C., April 20 /PRNewswire/ -- SmartGene, Inc., a provider of novel services for the management and analysis of genetic data, today announced a marketing and distribution collaboration with Virco Lab, Inc., to help US laboratories manage, analyze, and derive maximum benefit from their HIV sequences. Virco will market SmartGene, Inc.'s secure, Web-based service module, SmartGene(R) HIV, which is a unique, integrated, data management solution encompassing various interpretation algorithms, multiple genetic targets and cumulative resistance reporting.
The SmartGene HIV platform will allow laboratories using both SmartGene, Inc. and Virco services to send an order for interpretation of sequence data by Virco directly out of the SmartGene HIV module and then store the resulting virco(R)TYPE HIV-1 resistance reports within their SmartGene database.
"HIV clinicians and laboratorians understand the importance of longitudinal data to resistance assessment; they value the insight gained from reinterpreting sequences with updated algorithms and comparing results derived from different algorithms; they are interested in analyzing new genetic targets, such as Integrase and Envelope. SmartGene HIV exquisitely meets these needs," said David Ellis, President of SmartGene, Inc. "We have made excellent progress introducing our modules supporting bacterial and fungal identification by sequence analysis. As we expand the deployment of our services for virology in the US, we are delighted to enter this collaboration with Virco, a long-standing market leader for resistance testing and interpretation in the HIV field."
About SmartGene, Inc.
SmartGene, Inc. is the North American subsidiary of SmartGene GmbH, a privately-held company based in Zug, Switzerland, which provides its services worldwide. SmartGene provides web-based suites of functionality to facilitate sequence-based analysis fo
|SOURCE SmartGene, Inc.|
Copyright©2009 PR Newswire.
All rights reserved